Is Brooklyn ImmunoTherapeutics (BTX) Stock a Good Buy Below $15?

Brooklyn ImmunoTherapeutics (NYSEAMERICAN:BTX), which is involved in the development of treatments for rare diseases and cancers, has been in the middle of considerable changes in recent times.

Is Brooklyn ImmunoTherapeutics (BTX) Stock a Good Buy Below $15?

The main clinical program that Brooklyn is working on is IRX 2, which is involved with the development of treatments for head and neck cancers. The stock experienced a massive rally recently and went from $3.75 a share on April 1 to $80.67 on May 3. However, since then it has corrected sharply as well.

Related:  Ocugen (OCGN) Pops amid unveiling achievements on upcoming GIC 2020

It is important to note that around a year ago, the Brooklyn stock was trading at just over $2 a share. Recently, the stock has been in considerable focus among investors and also among investors from Reddit community WallStreetBets after it signed exclusive license agreements with Novellus Therapeutics and Factor Bioscience. Recently the company also announced Howard J. Federoff as its new Chief Executive Officer and that could also prove to be a positive trigger for the stock.

Anthony Gonzales

Biotech, Tech, and Crypto reporter Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.